Skip to menu Skip to content Skip to footer

2023

Conference Publication

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

An, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0793

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

2023

Conference Publication

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS.

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

2023

Conference Publication

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0543

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

2022

Conference Publication

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

An,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard, Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

2022

Conference Publication

Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission

Pudipeddi, Aviv, Fung, Caroline, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon, Begun, Jakob, Connor, Susan, Chetwood, John, Paramsothy, Sudarshan and Leong, Rupert (2022). Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission. International Digestive Disease Forum (IDDF), Hong Kong, China, 2-4 September 2022. London, United Kingdom: BMJ Group. doi: 10.1136/gutjnl-2022-IDDF.207

Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission

2021

Conference Publication

Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study

De Gregorio, M., Lee, T., Krishnaprasad, K., Amos, G., An, Y. K., Bastian-Jordan, M., Begun, J., Borok, N., Brown, D. J. M., Cheung, W., Connor, S., Gerstenmaier, J., Gilbert, L. E., Gilmore, R., Gu, B., Kutaiba, N., Lee, A., Mahy, G., Srinivasan, A., Thin, L., Thompson, A., Welman, C. J., Yong, E. X., De Cruz, P., van Langenberg, D., Sparrow, M. and Ding, N. S. (2021). Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study. 16th Congress of ECCO, Online, 2-3 & 8-10 July 2021. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjab076.523

Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study

2021

Conference Publication

Risks of under-treating and over-treating disease

An, Yoon-Kyo (2021). Risks of under-treating and over-treating disease. IBD 2020: Right Therapy, Right Patient, Right Time#Choosing Wisely, Proceedings of the Takeda IBD Symposium, Virtual, 5 September 2020. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.15458

Risks of under-treating and over-treating disease

2019

Conference Publication

Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

Haifer, C., Srinivasan, A., Menon, S., An, Y., Picardo, S., Van Langenberg, D., Begun, J., Ghaly, S. and Thin, L. (2019). Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, SA, Australia, 8–10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14801

Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

2019

Conference Publication

Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis

An, Y., Prince, D., Gardiner, F., Linedale, E., Andrews, J., Connor, S. and Begun, J. (2019). Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, South Australia, 8-10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14803

Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis

2016

Conference Publication

The incidence of 30-day adverse events after colonoscopy in an IBD population

An, Y. K., Wong, J., You, I. S., Mortimore, M., Hewett, D. G., Appleyard, M. N. and Begun, J. (2016). The incidence of 30-day adverse events after colonoscopy in an IBD population. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522

The incidence of 30-day adverse events after colonoscopy in an IBD population

2016

Conference Publication

Demyelination during infliximab therapy for crown's disease

An, Y. K., Allsop, S., Daveson, K.L. and Daveson, A. J. M. (2016). Demyelination during infliximab therapy for crown's disease. Australian Gastroenterology Week, Adelaide, SA, Australia, 10–12 October 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.13522

Demyelination during infliximab therapy for crown's disease

2012

Conference Publication

The impact of carbon dioxide insufflation on abdominal pain after colonoscopy

Finch, A., An, Y., Hewett, D. and Appleyard, M. (2012). The impact of carbon dioxide insufflation on abdominal pain after colonoscopy. RACP Future Directions in Health Congress 2012, Brisbane QLD, Australia, 6-9 May 2012. Richmond Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1445-5994.2012.02780.x

The impact of carbon dioxide insufflation on abdominal pain after colonoscopy

2012

Conference Publication

A systematic analysis of complication rates of colonoscopy in a teaching hospital

An, Y. K., Hewett, D. G., Vandeleur, A. E. and Appleyard, M. N. (2012). A systematic analysis of complication rates of colonoscopy in a teaching hospital. Digestive Disease Week (DDW), San Diego, CA, USA, May 19-22, 2012. NEW YORK: MOSBY-ELSEVIER.

A systematic analysis of complication rates of colonoscopy in a teaching hospital

2012

Conference Publication

A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital

Finch, A., An, Y., Hewett, D. and Appleyard, M. (2012). A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital. RACP Future Directions in Health Congress 2012, Brisbane, QLD, Australia, 6-9 May 2012. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1445-5994.2012.02780.x

A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital

2012

Conference Publication

The impact of carbon dioxide insufflation on abdominal pain after colonoscopy

An, Y. K., Hewett, D. G. and Appleyard, M. N. (2012). The impact of carbon dioxide insufflation on abdominal pain after colonoscopy. Digestive Disease Week (DDW), San Diego Ca, May 19-22, 2012. NEW YORK: MOSBY-ELSEVIER.

The impact of carbon dioxide insufflation on abdominal pain after colonoscopy

2011

Conference Publication

A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital

An, Y. K., Hewett, D. G., Sexton, J., Vandeleur, A. and Appleyard, M. N. (2011). A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital. Australian Gastroenterology Week 2011, Brisbane, Qld., Australia, 12-15 September 2011. Richmond, Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1746.2011.06821.x

A systematic analysis of complication rates of colonoscopy in an Australian teaching hospital

2011

Conference Publication

The impact of carbon dioxide insufflation on abdominal pain after colonoscopy

An, Y. K., Hewett, D. G. and Appleyard, M. N. (2011). The impact of carbon dioxide insufflation on abdominal pain after colonoscopy. Australian Gastroenterology Week 2011, Brisbane, Australia, 12-15 September 2011. MALDEN: MOSBY-ELSEVIER.

The impact of carbon dioxide insufflation on abdominal pain after colonoscopy